Research

Adherence

Continuous Positive Airway Pressure (CPAP) therapy has mixed and often limited effects on improving glycemic control (A1c, fasting glucose) and liver fat content in patients with OSA, T2DM, and MASLD, despite reducing sympathetic activity.

CPAP is essential for treating OSA and improving blood pressure, but it may not significantly lower blood sugar or liver fat on its own. If you have diabetes or fatty liver, focus on weight loss and medications, as CPAP alone may not reverse these conditions.

ModerateQualifiesMEDIUM confidence
a meta-analysis of RCTs examining CPAP effects on T2DM over a longer period concluded that CPAP does not significantly improve A1c or fasting glucose... When controlling for weight changes... the authors found no significant difference between the placebo and CPAP use on intrahepatic triglyceride content
Christina Gu et al. · Journal of Clinical Medicine · 2024

Why this rating

Supported by meta-analyses and RCTs showing mixed/negative results for metabolic endpoints.

Source

Potential Therapeutic Targets in Obesity, Sleep Apnea, Diabetes, and Fatty Liver Disease

Christina Gu et al. · Journal of Clinical Medicine · 2024

DOI 10.3390/jcm13082231

narrative_reviewCited 11×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →